Beyond taxanes: the next generation of microtubule-targeting agents-Reference-Cited by-同舟云学术

Beyond taxanes: the next generation of microtubule-targeting agents

Published:2011-11-24 Issue:3 Volume:133 Page:821-830
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Cortes Javier,Vidal Maria

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.springerlink.com/index/pdf/10.1007/s10549-011-1875-6

Reference66 articles.

1. Telli ML, Carlson RW (2009) First-line chemotherapy for metastatic breast cancer. Clin Breast Cancer 9(suppl 2):S66–S72

2. Surveillance epidemiology and end results. SEER stat fact sheets: breast. http://seer.cancer.gov/statfacts/html/breast.html#survival . Accessed 4 Nov 2010

3. Cardoso F, Senkus-Konefka E, Fallowfield L, Costa A, Castiglione M (2010) Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v15–v19

4. Yardley DA (2008) Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Clin Breast Cancer 8(6):487–492

5. Moreno-Aspitia A, Perez EA (2009) Treatment options for breast cancer resistant to anthracyclines and taxane. Mayo Clin Proc 84(6):533–545

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Potent Microtubule Targeting Agent by Structural Simplification of Natural Diazonamide;Journal of Medicinal Chemistry;2024-06-04

2. 3-epicaryoptin induces G2/M phase cell cycle arrest and apoptosis in human breast cancer cells by disrupting the microtubule network, anin vitroandin silicoinvestigation;2024-01-04

3. Personalized Medicine in Clinical Management of Breast Cancer: Where Do We Stand?;Molecular Biomarkers for Cancer Diagnosis and Therapy;2024

4. Expression of stathmin in asbestos-like fibers-induced mesothelioma: A preliminary report;HISTOL HISTOPATHOL;2023

5. Future prospects for mitosis-targeted antitumor therapies;Biochemical Pharmacology;2021-08